['NO CLINICALLY SIGNIFICANT INTERACTION OBSERVED', 'DRUG', 'DIDANOSINE DOSAGE', 'N', 'AUC OF COADMINISTERED DRUG (95% CI)', 'CMAX OF COADMINISTERED DRUG (95% CI)', 'DAPSONE, 100 MG SINGLE DOSE', '200 MG Q12H FOR 14 DAYS', '6 A', '\xe2\x86\x94', '\xe2\x86\x94', 'DELAVIRIDINE, 400 MG SINGLE DOSE SIMULTANEOUS', '125 OR 200 MG Q12H', '12 A', '\xe2\x86\x9332% B', '\xe2\x86\x9353% B', '1 HR BEFORE DIDANOSINE', '125 OR 200 MG Q12H', '12 A', '\xe2\x86\x9120%', '\xe2\x86\x9118%', 'GANCICLOVIR, 1000 MG Q8H, 2H AFTER DIDANOSINE', '200 MG Q12H', '12 A', '\xe2\x86\x9321%', 'NA', 'NELFINAVIR, 750 MG SINGLE DOSE, 1 H AFTER DIDANOSINE', '200 MG SINGLE DOSE', '10 A', '\xe2\x86\x9112%', '\xe2\x86\x94', 'RANITIDINE, 150 MG SINGLE DOSE, 2 H BEFORE DIDANOSINE', '375 MG SINGLE DOSE', '12 A', '\xe2\x86\x9316%', '\xe2\x86\x94', 'RITONAVIR, 600 MG Q12H FOR 4 DAYS', '200 MG Q12H FOR 4 DAYS', '12', '\xe2\x86\x94', '\xe2\x86\x94', 'STAVUDINE, 40 MG Q12H FOR 4 DAYS', '100 MG Q12H FOR 4 DAYS', '10 A', '\xe2\x86\x94', '\xe2\x86\x9117%', 'SULFAMETHOXAZOLE, 1000 MG SINGLE DOSE', '200 MG SINGLE DOSE', '8 A', '\xe2\x86\x9311% (-17, -4%)', '\xe2\x86\x9312% (-28, 8%)', 'TENOFOVIR, C 300 MG ONCE DAILY 1 H AFTER DIDANOSINE', '250 D OR 400 MG ONCE DAILY FOR 7 DAYS', '14', '\xe2\x86\x94', '\xe2\x86\x94', 'TRIMETHOPRIM, 200 MG SINGLE DOSE', '200 MG SINGLE DOSE', '8 A', '\xe2\x86\x9110% (-9, 34%)', '\xe2\x86\x9322% (-59, 49%)', 'ZIDOVUDINE, 200 MG Q8H FOR 3 DAYS', '200 MG Q12H FOR 3 DAYS', '6 A', '\xe2\x86\x9310% (-27, 11%)', '\xe2\x86\x9316.5% (-53, 47%)', '\xe2\x86\x91 INDICATES INCREASE. \xe2\x86\x93INDICATES DECREASE. \xe2\x86\x94 INDICATES NO CHANGE, OR MEAN INCREASE OR DECREASE OF <10%. A HIV-INFECTED PATIENTS. B THIS RESULT IS PROBABLY RELATED TO THE BUGGER AND IS NOT EXPECTED TO OCCUR WITH DIDANOSINE DELAYED-RELEASE CAPSULES. C TENOFOVIR DISOPROXIL FUMARATE. D PATIENTS <60 KG WITH CREATININE CLEARANCE >60 ML/MIN. NA NOT AVAILABLE']G Q12H FOR 4 DAYS', '100 MG Q12H FOR 4 DAYS', '10', '\xe2\x86\x94', '\xe2\x86\x94', 'SULFAMETHOXAZOLE, 1000 MG SINGLE DOSE', '200 MG SINGLE DOSE', '8 E', '\xe2\x86\x94', '\xe2\x86\x94', 'TRIMETHOPRIM, 200 MG SINGLE DOSE', '200 MG SINGLE DOSE', '8 E', '\xe2\x86\x94', '\xe2\x86\x9117% (-23, 77%)', 'ZIDOVUDINE, 200 MG Q7H FOR 3 DAYS', '200 MG Q12H FOR 3 DAYS', '8 E', '\xe2\x86\x94', '\xe2\x86\x94', '\xe2\x86\x91 INDICATES INCREASE \xe2\x86\x93 INDICATES DECREASE \xe2\x86\x94 INDICATES NO CHANGE, OR MEAN INCREASE OR DECREASE OF <10%. A PARELLEL-GROUP DESIGN; ENTRIES ARE SUBJECTS RECEIVING COMBINATION AND CONTROL REGIMENS, RESPECTIVELY. B TENOGOVIR DISOPROXIL FUMARATE C PATIENTS <60 KG WITH CREATININE CLEARANCE >60 ML/MIN. D 90% CI E HIV-INFECTED PATIENTS N/A NOT AVAILABLE']